Anixa Biosciences Inc (NASDAQ:ANIX) Receives $9.00 Average PT from Analysts

Shares of Anixa Biosciences Inc (NASDAQ:ANIX) have earned an average recommendation of “Moderate Buy” from the five research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $9.00.

Several analysts have recently commented on ANIX shares. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a report on Thursday, September 11th. Zacks Research upgraded shares of Anixa Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. D. Boral Capital reissued a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a report on Tuesday, October 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday.

Anixa Biosciences Trading Down 2.4%

NASDAQ ANIX opened at $4.10 on Friday. Anixa Biosciences has a 1-year low of $2.07 and a 1-year high of $4.98. The company has a 50 day moving average of $3.90 and a 200-day moving average of $3.35. The firm has a market cap of $134.96 million, a price-to-earnings ratio of -11.71 and a beta of 0.66.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Wednesday, September 10th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. On average, analysts forecast that Anixa Biosciences will post -0.41 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ANIX. Bank of America Corp DE boosted its position in Anixa Biosciences by 1.7% in the 3rd quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock valued at $706,000 after buying an additional 3,645 shares during the last quarter. GSA Capital Partners LLP raised its position in shares of Anixa Biosciences by 4.9% during the third quarter. GSA Capital Partners LLP now owns 81,897 shares of the company’s stock worth $270,000 after acquiring an additional 3,790 shares during the last quarter. Prosperity Wealth Management Inc. lifted its stake in shares of Anixa Biosciences by 14.5% during the third quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock valued at $138,000 after acquiring an additional 5,300 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in Anixa Biosciences by 2,000.0% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after acquiring an additional 10,000 shares during the last quarter. Finally, NewEdge Advisors LLC bought a new position in Anixa Biosciences in the second quarter valued at about $33,000. Institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.